Patients who have had an echocardiogram performed within 6 months prior to step 2 randomization must have ventricular ejection fraction (left ventricular ejection fraction [LVEF]) >= 50% or >= within normal limits for the institution
Patients must have ejection fraction >= 45% based on echocardiogram performed within 28 days prior to registration
Transthoracic echocardiogram with ejection fraction > 50%
Cardiac ejection fraction (left ventricular ejection fraction [LVEF]) >= 50% by echocardiogram =< 28 days prior to registration
Left ventricular ejection fraction (LVEF) >= 50% calculated by echocardiogram (ECHO)
EXPANDED ACCESS COHORT: Participants must have adequate cardiac function, defined as:\r\n* Left ventricular ejection fraction (LVEF) >= 50% as determined by echocardiogram (ECHO) or MUGA\r\n* QTcF =< 480 msec on screening electrocardiogram (ECG)
PART I: Baseline left ventricular ejection fraction (LVEF) by 2 dimensional (2D) echocardiogram >= 53%
PART II: Baseline LVEF by 2D echocardiogram >= 55%
Echocardiogram demonstrated left ventricular ejection fraction >= 40%.
Left ventricular ejection fraction < 40% as measured on transthoracic echocardiogram
Left ventricular ejection fraction (LVEF) < 50% as assessed by echocardiogram or radionuclide angiography
Within two weeks prior to enrollment: Left ventricular ejection fraction (LVEF) >= 50% as determined an echocardiogram
Left ventricular ejection fraction (LVEF) < 50% as assessed by echocardiogram or radionuclide angiography
Left ventricular ejection fraction (LVEF as determined by cardiac echo or MUGA scan) below the normal limits of the institutions specific testing range. This assessment may be repeated once at the discretion of the Investigator with the approval of the Sponsor.
Adequate cardiac function, defined as left ventricular ejection fraction (LVEF) of ? 50% as assessed by echocardiogram or MUGA scan, or LVEF of 45-49% and clearance by a cardiologist; if subject receives cardiotoxic chemotherapy after enrollment, repeat echocardiogram or MUGA is required to reestablish eligible LVEF
Echocardiogram demonstrating left ventricular ejection fraction (LVEF) >= 35%
Left ventricular ejection fraction (LVEF) ejection fraction (EF) >= of 50% (by echocardiogram or MUGA scan within 12 weeks of registration), within 2 weeks of registration (except where specified otherwise)
Left ventricular ejection fraction (LVEF as determined by cardiac echo or MUGA scan) below the normal limits of the institutions specific testing range. This assessment may be repeated once at the discretion of the Investigator with the approval of the Sponsor.
Left ventricular ejection fraction (LVEF) < 50% as assessed by echocardiogram or radionuclide angiography
Patients with left ventricular ejection fraction < 50% or 10% decrease from baseline on echocardiogram after anthracycline based chemotherapy
Left ventricular ejection fraction (LVEF) assessed by echocardiogram within 3 months prior to initiation of study treatment indicates an LVEF of >= 50%
Left ventricular ejection fraction (LVEF) < 50% (evaluated by echocardiogram or magnetic resonance imaging [MRI])
Left ventricular ejection fraction: < 40% estimated by echocardiogram (ECHO)
LVEF < 50% and >= 40% documented in echocardiogram done within the last 30 days
RECIPIENT: Left ventricular ejection fraction > 40%, preferably by 2-dimensional (2-D) echocardiogram (echo) obtained within 28 days of enrollment
Left ventricular ejection fraction > 40%, preferably by two dimensional (2-D) echocardiogram (ECHO), obtained within 90 days of enrollment; if the patient has radiological evidence of aortic, renal artery, or coronary artery vasculitis, a left ventricular ejection fraction > 30% is acceptable
Normal echocardiogram (ECHO) (Left ventricular ejection fraction [LVEF] has to be within normal, institutional limits)
Left ventricular ejection fraction (LVEF) >= 45% as measured by echocardiogram during screening evaluation
Echocardiogram with normal ejection fractions
Left ventricular ejection fraction (LVEF) assessment (eg, echocardiogram, radionuclide ventriculogram scan [MUGA], first-pass technique) performed within 3 months prior to initiation of study treatment indicates an LVEF of >= 50%
Symptomatic congestive heart failure or radionuclide ventriculogram (RVG) or echocardiogram determined left ventricular ejection fraction of < 30%, active angina pectoris, or uncontrolled hypertension
Within 30 days of registration: Left ventricular ejection fraction (echocardiogram within 6 months permitted) >= 40%
Subjects who have a left ventricular ejection fraction (LVEF) < 50%, as assessed by echocardiogram performed at screening
Patients must have either echocardiogram (ECHO) with ejection fraction >= 45% within 28 days prior to registration
Normal echocardiogram (ECHO) (left ventricular ejection fraction [LVEF] has to be within normal, institutional limits)
Left Ventricular Shortening Fraction (LVSF) ? 28% confirmed by echocardiogram, or Left Ventricular Ejection Fraction (LVEF) ? 45% confirmed by echocardiogram or MUGA within 7 days of screening
Hemodynamically stable and Left Ventricle Ejection Fraction (LVEF) ? 45% confirmed by echocardiogram or Multigated Radionuclide Angiography (MUGA)
Left ventricular ejection fraction (LVEF) ? 40% as measured by MUGA scan or 2-D ECHO within 28 days prior to start of therapy and no clinically significant abnormalities on a 12-lead ECG
Left ventricular ejection fraction (LVEF) ? 40% as measured by MUGA scan or 2-D ECHO within 28 days prior to start of therapy and no clinically significant abnormalities on a 12-lead ECG
Symptomatic congestive heart failure or evidence of left ventricular dysfunction (ejection fraction < 40%) as measured by gated radionucleotide ventriculogram or echocardiogram; active angina pectoris, or uncontrolled hypertension
Active symptomatic ischemic heart disease, myocardial infarction or congestive heart failure within the past year; if echocardiogram (ECHO) is obtained the left ventricular ejection fraction (LVEF) should exceed 40%
Baseline ejection fraction ? 50% as assessed by echocardiogram or MUGA.
PHASE II: Left ventricular ejection fraction (LVEF) >= 50% calculated by echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) of at least 50% as determined by MUGA or echocardiogram
Baseline (< 1 month before treatment) cardiac left ventricular function with resting ejection fraction of less than 50% measured by echocardiogram
Left ventricular ejection fraction (LVEF) < 50% as assessed by echocardiogram or radionuclide angiography
Left ventricular ejection fraction >= 50%, as determined by radionuclide ventriculography (RVG) or echocardiogram within 60 days prior to initiation of protocol therapy
Screening Left ventricular ejection fraction (LVEF) >/= 50% on echocardiogram (ECHO) or multiple-gated acquisition (MUGA) after receiving neoadjuvant chemotherapy and no decrease in LVEF by more than 15% absolute points from the pre-chemotherapy LVEF. Or, if pre-chemotherapy LVEF was not assessed, the screening LVEF must be >/= 55% after completion of neoadjuvant chemotherapy.
Normal cardiac function defined as either a MUGA or echocardiogram (ECHO) with left ventricular ejection fraction (LVEF) in normal institutional range (MUGA 50%; ECHO 55%)
Left ventricular ejection fraction >= 50%, as determined by RVG (MUGA) or echocardiogram within 60 days prior to initiation of extension phase therapy (all cohorts)
Active symptomatic ischemic heart disease, myocardial infarction or congestive heart failure within the past year; if echocardiogram (ECHO) is obtained, the left ventricular ejection fraction (LVEF) should exceed 40%
LVEF < 45% by echocardiogram
Left ventricular ejection fraction <50% as determined by echocardiogram (ECHO) performed at screening or within 30 days prior to C1D1
Patients will be ineligible for treatment on this protocol if:\r\n* There is a history of a recent myocardial infarction (within one year)\r\n* There is a history of a past myocardial infarction (more than one year ago) along with current coronary symptoms requiring medications and/or evidence of depressed left ventricular function (left ventricular ejection fraction [LVEF] < 45% by echocardiogram [ECHO])\r\n* There is a current history of angina/coronary symptoms requiring medications and/or evidence of depressed left ventricular function (LVEF < 45% by ECHO)\r\n* There is clinical evidence of congestive heart failure requiring medical management (irrespective of ECHO results)
Adequate heart function with echocardiogram demonstrating ejection fraction >= 45% with no evidence of systolic dysfunction
Baseline cardiac echocardiogram scan with left ventricular ejection fraction (LVEF) of >= 50%
RECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Cardiac function: \r\n* Left ventricular ejection fraction >= 50 by gated radionuclide study OR shortening fraction of >= 27% by echocardiogram\r\n* Patient has no ventricular arrhythmias except for benign premature ventricular contractions\r\n* Patient has a corrected QT (QTc) interval =< 450 ms
Left ventricular ejection fraction (LVEF) < 45% as determined by MUGA scan or echocardiogram (ECHO).
Left ventricular ejection fraction (LVEF) >50% per ECHO or MUGA for patients on the sunitinib arms (Parts 2e and f).
Patients with a left ventricular cardiac ejection fraction < 50% as assessed by an echocardiogram or MUGA scan
Left ventricular ejection fraction < 50% as assessed by echocardiogram or radionuclide angiography.
Subjects with a left ventricular cardiac ejection fraction < 50% as assessed by an echocardiogram or MUGA scan
Left ventricular ejection fraction (LVEF) ?50% by echocardiogram
Left ventricular ejection fraction (LVEF) <40%, as determined by screening echocardiogram (echocardiogram results obtained within 90 days prior to screening are acceptable)
Left ventricular ejection fraction (LVEF) < 50% by MUGA or echocardiogram
Adequate cardiac function measured by left ventricular ejection fraction (LVEF) > 50%; if asymptomatic, pre-transplant echocardiogram is adequate; if symptomatic, echocardiogram needs to be repeated
LVEF (measured by Echocardiogram) > 50%
Spirometry with at least 70% of predicted volumes (including FEV1). A left ventricular ejection fraction (LVEF) of 45% or more. All patients will have a screening 2-D Echocardiogram as part of eligibility screening.
History of myocardial infarction (MI) or NYHA Class II-IV congestive heart failure within 6 months of the administration of the first dose of ARQ 092 (MI occurring >6 months of the first dose of ARQ 092 will be permitted); Grade 2 or worse conduction defect (eg right or left bundle branch block); left ventricular ejection fraction (LVEF) < 50% assessed by echocardiogram/MUGA scan
MUGA/Echocardiogram Left Ventricular Ejection Fraction < 50%.
If in Arm D (doxorubicin and cyclophosphamide), left ventricular ejection fraction (LVEF) >= 50% as measured by echocardiogram (ECHO) within 4 weeks prior to study drug administration
Ejection fraction < 50% on echocardiogram (ECHO) or MUGA
Baseline screening echocardiogram (echo) left ventricular ejection fraction (LVEF) =< 50
Left ventricular ejection fraction < 45% (evaluated by echocardiogram or MUGA scan)
Left ventricular ejection fraction < 50% (evaluated by echocardiogram or MUGA)
Shortening fraction of >= 27% by echocardiogram OR ejection fraction of >= 50% by multi-gated acquisition (MUGA)
Left ventricular ejection fraction > 50% as measured by echocardiogram or multi gated acquisition (MUGA) scan
Cardiac ejection fraction >= 50% (for HER2+ patients) as assessed by echocardiogram, multi gated acquisition scan (MUGA) scan, or cardiac magnetic resonance imaging (MRI)
Patients must not have a cardiac ejection fraction < 45% or the presence of New York Heart Association stage III or IV heart failure within 14 days prior to registration; either echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA) may be used to determine ejection fraction
Patients with a cardiac ejection fraction (as measured by either Multi Gated Acquisition [MUGA] or echocardiogram [EKG]) < 40%
Baseline ejection fraction ? 50% as assessed by echocardiogram or multi-gated acquisition (MUGA) scan.
Normal left ventricular ejection fraction of >= 50% estimated by multi gated acquisition (MUGA) scan or echocardiogram
Left ventricular ejection fraction >= 50% on echocardiogram or multi gated acquisition scan (MUGA) scan
Ejection fraction of < 45% by either multi gated acquisition scan (MUGA) or echocardiogram (ECHO)
Ejection fraction < 40% obtained by either multi gated acquisition scan (MUGA) or echocardiogram
Normal cardiac ejection fraction (> 50%) by multi gated acquisition scan (MUGA) or echocardiogram
Adequate cardiac function defined as an ejection fraction of >= 50% by multi gated acquisition scan (MUGA) scan or echocardiogram and a corrected QT (QTc) interval of =< 450 ms for men and =< 460 ms for women
Patients with a cardiac ejection fraction (as measured by either multi-gated acquisition [MUGA] or echocardiogram) < 40%
A cardiac evaluation with an electrocardiogram showing no ischemic changes or abnormal rhythm and an ejection fraction of >= 50% established by multi-gated acquisition scan (MUGA) or echocardiogram
Ejection fraction measured by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)\r\n> 50%.
Cardiac ejection fraction >= 50%, no evidence of pericardial effusion as determined by an echocardiogram (ECHO) or multiple-gated acquisition (MUGA), and no clinically significant electrocardiography (ECG) findings
Adequate cardiac function defined as an ejection fraction on echocardiogram (ECHO) or multi-gated acquisition (MUGA) that is at or above the institutional normal limits
CELL PROCUREMENT: Subjects must not have left ventricular ejection fraction of < 40% (shortening fraction < 27% for pediatric subjects) as measured by echocardiogram or multi-gated acquisition (MUGA)
Ejection fraction of >= 50% by echocardiogram or multi-gated acquisition (MUGA) scan
A cardiac evaluation with an electrocardiogram showing no ischemic changes or abnormal rhythm and an ejection fraction of 50% established by multi-gated acquisition scan (MUGA) or echocardiogram
Ejection fraction > 45% by either multi-gated acquisition scan (MUGA) scan or echocardiogram
Multi-gated acquisition (MUGA) scan or echocardiogram (ECHO) >= ejection fraction (EF) of 50%
Ejection fraction (EF) >= 50% on multi gated acquisition (MUGA) scan or echocardiogram
Has a shortening fraction of >27% or an ejection fraction of ?50% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan and New York Heart Association (NYHA) Class ?2
Cardiac ejection fraction >= 50% by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA)
Patients with a cardiac ejection fraction (as measured by either multi-gated acquisition [MUGA] scan or echocardiogram) < 40%; (Note: patients who have had prior anthracycline exposure of > 250 mg/m^2 may be eligible after discussion with the principal investigator [PI])
For children with neuroblastoma (NBL): normal ejection fraction (> 55%) documented by echocardiogram or radionuclide multi-gated acquisition (MUGA) evaluation OR normal fractional shortening (> 27%) documented by echocardiogram; for subjects with paraganglioma/ pheochromocytoma: no clinically significant cardiac dysfunction
Cardiac ejection fraction of >= 50% by echocardiogram or multi gated acquisition scan (MUGA)
Ejection fraction measured by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) >= 50%
Ejection fraction measured by echocardiogram or multi gated acquisition scan (MUGA) > 45% (evaluation within 6 weeks of screening does not need to be repeated)
Cardiac ejection fraction >= 40% (by either cardiac echocardiogram [echo] or multi gated acquisition [MUGA] scan); documentation of recent (=< 6 months from screening) outside reports is acceptable
Echocardiogram (ECHO) or multi gated acquisition scan (MUGA): ejection fraction of >= 50% AND no finding of abnormal wall motion (i.e. report does not indicate that wall motion is “abnormal” or “altered”)
Normal cardiac function as defined by a normal ejection fraction by multi gated acquisition scan (MUGA) or echocardiogram
Adequate cardiac function (ejection fraction [EF] > 50%) based on multi gated acquisition (MUGA) scan or 2 dimensional-echocardiogram (2D-Echo)
Patients must have normal baseline cardiac function based upon echocardiogram or gated blood pool scan (multigated acquisition scan [MUGA]) with an ejection fraction >= 50%
Cardiac ejection fraction of >= 50% by echocardiogram or multi gated acquisition scan (MUGA)
Patients must obtain a base line echocardiogram or multi gated acquisition scan (MUGA) and require the left ventricular ejection fraction to be within normal limits (or 50% or higher)
Cardiac ejection fraction >= 50% by multiple gate acquisition (MUGA) scan and/or by echocardiogram
Cardiac dysfunction documented by an ejection fraction less than the lower limit of the facility normal by multi-gated acquisition (MUGA) scan, or less than 50% by echocardiogram
Shortening fraction > 25% by echocardiogram or ejection fraction above the institutional lower limit of normal by multi gated acquisition scan (MUGA)
Multi gated acquisition scan (MUGA) > 45% injection fraction
Left ventricular ejection fraction (EF) > 40% by echocardiogram, multi-gated acquisition (MUGA), or cardiac magnetic resonance (MR)
Cardiac function:\r\n* Normal ejection fraction (>= 55%) documented by either echocardiogram or radionuclide multi gated acquisition scan (MUGA) evaluation; OR \r\n* Normal fractional shortening (>= 27%) documented by echocardiogram
Echocardiogram or multi gated acquisition (MUGA) scan demonstrating an ejection fraction >= 45%
Baseline (< 1 month before treatment) cardiac left ventricular function with resting ejection fraction of less than 50% measured by multigated blood pool imaging of the heart (multi gated acquisition scan [MUGA] scan) or echocardiogram
Ejection fraction measured by echocardiogram or multi gated acquisition scan (MUGA) > 50%
Adequate cardiac function as defined by either of the following:            \r\n* An echocardiogram demonstrating an ejection fraction within normal limits\r\n* A multi gated acquisition (MUGA) scan demonstrating an ejection fraction within normal limits
Patients must have a cardiac ejection fraction > 45% on two-dimensional (2D) echocardiography or multi gated acquisition scan (MUGA) obtained within 28 days of study enrollment
Poor cardiac function: left ventricular ejection fraction < 50% as determined by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) or a shortening fraction below 27%
Has a shortening fraction of >27% or an ejection fraction of ?50% by echocardiogram or multi-gated acquisition scan
Patients must have a cardiac ejection fraction >= institutional lower limit of normal (ILLN) by multi gated acquisition (MUGA) scan or 2-dimensional (D) echocardiogram (ECHO) within 42 days prior to registration
Ejection fraction of >= 45% by either multi-gated acquisition (MUGA) scan or echocardiogram (ECHO)
Subjects with major cardiac illness multi-gated acquisition scan (MUGA) or echocardiogram (ECHO) < 50% ejection fraction (EF)
Subjects with multi gated acquisition scan (MUGA) < 50% ejection fraction (EF)
Ejection fraction >= 47% by radionuclide angiogram (multi gated acquisition scan [MUGA]); Note: the echocardiogram (or MUGA) may be done within 28 days prior to enrollment
Left ventricular ejection fraction > 45% by either multi gated acquisition scan (MUGA) scan or echocardiogram; if ejection fraction (EF) is < 50%, a cardiology consult should be placed and echocardiogram performed if not already done
Ejection fraction of < 45% by either multi gated acquisition scan (MUGA) or echocardiogram (ECHO)
For patients in stratum A, an echocardiogram (ECHO) or multi gated acquisition scan (MUGA) demonstrating ejection fraction (EF) > 50% is required within 28 days prior to study drug administration
Left ventricular ejection fraction of >= 40% by multi-gated acquisition (MUGA) scan or echocardiogram
Baseline ejection fraction >= 50% by multi gated acquisition scan (MUGA) scan or echocardiogram performed =< 60 days prior to registration
Subjects must have a multi gated acquisition scan (MUGA) and/or echocardiogram (ECHO) or cardiac magnetic resonance (MR); the required minimum standards include MUGA or ECHO or cardiac MR showing an ejection fraction (EF) of 40%; those with an EF 40-49% must also have a cardiologist consult and assist with management
Echocardiogram (Echo) or multi-gated acquisition scan (MUGA) with ejection fraction > 50%
Ejection fraction on echocardiogram (Echo) or multi gated acquisition scan (MUGA) > 50%
An echocardiogram (ECHO) or multiple gated acquisition (MUGA) demonstrating ejection fraction (EF) > 50%
Subjects with an evaluation of cardiac function indicating normal function on MUGA scan (multiple gated acquisition scan) or other methodology; AND
Patients must have a multi gated acquisition scan (MUGA) or echocardiogram within 90 days prior to starting treatment and the ejection fraction must be >= 45%
Normal cardiac function as demonstrated by a left ventricular ejection fraction >= 50% on echocardiogram or multi gated acquisition (MUGA) scan
Ejection fraction < 50%, as determined by echocardiogram or multi gated acquisition scan (MUGA)
Left ventricular ejection fraction >= 50% OR shortening fraction of >= 27% demonstrated on 2 dimensional (2D) echocardiogram or multi gated acquisition scan (MUGA)
Cardiac ejection fraction >= 50% as measured by echocardiogram of multiple gated acquisition scan (MUGA) scan
Ejection fraction (EF) > 50% by multi gated acquisition scan (MUGA)
Patients must have an echocardiogram or multi gated acquisition (MUGA) scan; if the ejection fraction is < 40%, the patient will not be eligible; if the ejection fraction is 40-50%, patients must have an exercise echocardiogram or dobutamine-echocardiogram (echo) with a normal response to exercise
Cardiac ejection fraction >= 50% by multi-gated acquisition (MUGA) scan and/or by echocardiogram
Adequate left ventricular function with ejection fraction >= 40% by echocardiogram or multi-gated acquisition scan (MUGA) scan
Patients with a cardiac ejection fraction (as measured by either multi gated acquisition scan [MUGA] or echocardiogram) less than 40%
Measured cardiac ejection fraction > or = to 50% or the institutional lower limit of normal by echocardiogram or MUGA scan.
Ejection fraction by multi gated acquisition scan (MUGA) scan or echocardiogram >= lower limit of institutional normal
Baseline (< 1 month before treatment) cardiac left ventricular function with resting ejection fraction of less than 50% measured by multigated blood pool imaging of the heart (multi gated acquisition scan [MUGA] scan) or echocardiogram
Adequate cardiac function with LVEF >=50% as assessed by echocardiogram (ECHO) or Multi Gated Acquisition Scan (MUGA.
Screening calculated ejection fraction greater than or equal to the institutional lower limit of normal by multiple gated acquisition (MUGA) scan or by echocardiogram (ECHO); a MUGA is preferred because of greater reproducibility
Patients must have either echocardiogram (ECHO) or multi gated acquisition scan (MUGA) with ejection fraction >= 45% within 28 days prior to registration
Cardiac ejection fraction · 40% (by either cardiac echocardiogram [ECHO] or multi gated acquisition [MUGA] scan)
Patients with prior anthracycline exposure must have a baseline multi gated acquisition scan (MUGA) or echocardiogram prior to study entry
Normal cardiac function (ejection fraction >= lower limit of normal) as determined by multi-gated acquisition scan (MUGA) or echocardiogram
Cardiac left ventricular ejection fraction > 40% by echocardiogram or multi gated acquisition scan (MUGA)
All patients must have an echo or multi gated acquisition scan (MUGA) scan showing ejection fraction (EF) > 50% and normal troponin and creatine kinase (CK) myoglobin binding (MB) (echo may be done at the time of stress test as a stress echo); within 6 months of starting treatment; however if the patient has received cardiotoxic chemotherapy such as Adriamycin, they must have had an echo or MUGA scan since completing this treatment
Echocardiogram or multi gated acquisition (MUGA) scan with ejection fraction within normal institution limits within 28 days of registration
Ejection fraction measured by echocardiogram or multi gated acquisition scan (MUGA) > 45%
A cardiac evaluation with an electrocardiogram showing no ischemic changes or abnormal rhythm and an ejection fraction of 50% established by multi gated acquisition scan (MUGA) or echocardiogram
Left ventricular ejection fraction must be > 45% assessed by multi-gated acquisition scan (MUGA) scan or echocardiogram; no myocardial infarction within 6 months of transplant evaluation
Cardiac ejection fraction < 30% on multi gated acquisition scan (MUGA) scan or cardiac echocardiogram (echo) or active symptomatic coronary artery disease; patients with cardiac disease should be evaluated with appropriate cardiac studies and/or cardiology consultation as clinically indicated
Subjects with major cardiac illness multi-gated acquisition scan (MUGA) < 50% ejection fraction (EF)
Estimated cardiac ejection fraction >= 50% by echocardiogram or multi gated acquisition scan (MUGA)
Ejection fraction >= lower limit of normal (LLN) by echocardiogram (ECHO) (preferred) or multi gated acquisition scan (MUGA)
Left ventricular ejection fraction (LVEF) below institutional lower limit of normal (LLN) or below 50%, whichever is lower, as determined by echocardiogram or multi-gated acquisition (MUGA) scan within 4 weeks of randomization
Cardiac ejection fraction (left ventricular ejection fraction [LVEF]) >= institutional lower limit of normal by multi gated acquisition scan (MUGA)/radionuclide ventriculogram (RVG) or echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) assessment must be performed within 90 days prior to randomization; (LVEF assessment performed by 2-dimensional [D] echocardiogram is preferred; however, multi gated acquisition [MUGA] scan may be substituted based on institutional preferences;) the LVEF must be >= 50% regardless of the cardiac imaging facility's lower limit of normal
Patients must have a left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (ILLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) within 28 days prior to registration
Patients must have an echocardiogram (ECHO) or a nuclear study (multi-gated acquisition scan [MUGA] or first pass) within 4 weeks (28 days) prior to registration to treatment and must not have a left ventricular ejection fraction (LVEF) < institutional lower limit of normal (LLN); if the LLN is not defined at a site, the LVEF must be > 50% for the patient to be eligible
Cardiopulmonary dysfunction, including inadequate left ventricular ejection function at baseline, less than 50% by either echocardiogram or multiple-gated acquisition scan
Left ventricular ejection fraction (LVEF) determined by echocardiogram or multi-gated acquisition scan ? 50%
Cardiac function: Left ventricular ejection fraction (LVEF) > 40%; or LV shortening fraction > 26% by cardiac echocardiogram or by Multi Gated Acquisition Scan (MUGA).
Left ventricular ejection fraction (LVEF) within 5 absolute percentage points of institutional standard of normal as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 28 days prior to study registration (i.e., if the institutional normal is 50%, subject’s LVEF may be as low as 45% to be eligible for the study)
Left ventricular ejection fraction (LVEF) of 50% or greater, as measured by echocardiogram (ECHO) or multiple gated acquisition (MUGA) scan, within 28 days before the first dose of TAK-580
Left ventricular ejection fraction (LVEF) < 45% as determined by multi-gated acquisition scan (MUGA) or echocardiogram (ECHO).
Participant has a left ventricular ejection fraction (LVEF) <50% as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO);
Baseline left ventricular ejection fraction (LVEF) greater than or equal to (>=) 53 percent (%) measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scans
Patients must have normal left ventricular systolic function, as demonstrated by a transthoracic echocardiogram or multi-gated acquisition scan (MUGA) scan showing a normal left ventricular ejection fraction
Cardiac: Left ventricular ejection fraction (LVEF) at rest ? 40%. For patients aged < 13 years, shortening fraction (SF) ? 26% by echocardiogram or Multi Gated Acquisition Scan (MUGA) may be substituted for LVEF.
Patients must not have presence of class III or IV heart failure, according to New York Heart Association classifications, or a known left ventricular ejection fraction of less than 50%; Note: left ventricular ejection fraction (LVEF) evaluation by echocardiogram or multi-gated acquisition scan (MUGA) is not required prior to registration
Normal cardiac function, as determined by left ventricular ejection fraction (LVEF) >= institutional lower limit of normal on echocardiogram or multi-gated acquisition scan (MUGA) within 1 month of registration
Left ventricular ejection fraction (LVEF) > 50% as assessed by echocardiogram or MUGA (multi gated acquisition scan)
Screening calculated LVEF of ?50% by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan
Baseline multi-gated acquisition scan (MUGA) or echocardiogram scans with left ventricular ejection fraction (LVEF) of > 50%.
Left ventricular ejection fraction (LVEF) above institutional lower limit of normal (by echocardiogram or multi-gated acquisition [MUGA] scan within 90 days of registration)
Left ventricular ejection fraction determined by echocardiogram or multiple-gated acquisition scan (MUGA) (cardiac scan) must be 50% or higher
Left ventricular ejection fraction (LVEF) > 40% or LV shortening fraction > 26% by cardiac echocardiogram or by multi-gated acquisition (MUGA) scan
Patients with New York Heart Association (NYHA) class III or IV congestive heart failure or left ventricular ejection fraction (LVEF) < 40% by echocardiogram or multi-gated acquisition (MUGA) scan
Left ventricular ejection fraction (LVEF) >= 40% as assessed by echocardiogram (ECHO) or multiple uptake gated acquisition (MUGA) scan performed within 1 month before starting lymphodepleting chemotherapy
Left ventricular ejection fraction (LVEF) assessment by 2-dimensional (D) echocardiogram or multi-gated acquisition (MUGA) scan performed within 90 days prior to registration must be >= 50%
Left ventricular ejection fraction (LVEF) >= 50% measured by multiple-gated acquisition scan (MUGA) or echocardiogram (ECHO)
Symptomatic congestive heart failure (New York Heart Association III-IV) or documented cardiomyopathy with left ventricular ejection fraction (LVEF) <50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO) at screening. MUGA/ ECHO to be performed within 28 days prior to registration.
Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multi-gated acquisition (MUGA)
Left ventricular ejection fraction (LVEF) >/= 50 percent (%) on cardiac multiple-gated acquisition (MUGA) scan or cardiac echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) within 5 absolute percentage points of institutional standard of normal (50-70%) as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 4 weeks prior to first study drug administration (ie, if the institutional normal is 50%, subject’s LVEF may be as low as 45% to be eligible for the study)
Left ventricular ejection fraction (LVEF) assessment (i.e., 2 dimensional [2-D] echocardiogram or multi-gated acquisition [MUGA] scan) performed within 12 weeks prior to study registration indicates an LVEF >= 50% regardless of the cardiac imaging facility’s lower limit of normal
Patients must have a shortening fraction >= 27% or left ventricular ejection fraction >= 50% measured by echocardiogram (ECHO) or measured by multiple-gated acquisition scans (MUGA)
Left ventricular ejection fraction (LVEF) >= 45% by multi-gated acquisition scan (MUGA) or rest echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) of the institutional standard of normal as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 4 weeks prior to first study drug administration
Left ventricular ejection fraction >= 50% by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) within 6 months of study entry
Adequate cardiac function, defined as left ventricular ejection fraction (LVEF) >= 35% as assessed by echocardiogram (ECHO) or multiple uptake gated acquisition (MUGA)
Left ventricular ejection fraction (LVEF) >= 50% measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA)
Multi-gated acquisition scan (MUGA) or echocardiogram (ECHO) for left ventricular ejection fraction (LVEF) >= 45%
Left ventricular ejection fraction >= 40% as confirmed by echocardiogram (ECHO)/multi gated acquisition scan (MUGA)
Baseline multi-gated acquisition (MUGA) or echocardiogram showing left ventricular ejection fraction (LVEF) >= 50% within 6 weeks prior to initiation of neoadjuvant chemotherapy
Baseline multi gated acquisition scan (MUGA) or echocardiogram scans with left ventricular ejection fraction (LVEF) of > 50%
Baseline multi-gated acquisition (MUGA) scan or echocardiogram showing left ventricular ejection fraction (LVEF) >= 50% at least 6 weeks prior to initiation of NACT
Left ventricular ejection fraction (LVEF) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) or magnetic resonance imaging (MRI) >= 40%
Patients must have normal cardiac function, as evidenced by a left ventricular ejection fraction (LVEF) within institutional normal limits; echocardiogram may be used if multi gated acquisition (MUGA) scan is not available, but the same test must be used throughout the study to evaluate LVEF
Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (Echo) or multi gated acquisition scan (MUGA)
Left ventricular ejection fraction (LVEF) >= 50% by echocardiogram (ECHO) or multi gated acquisition (MUGA) scan
The left ventricular ejection fraction (LVEF) assessment by 2-D echocardiogram or multi-gated acquisition (MUGA) scan performed within 90 days prior to study entry must be greater than or equal to 50% regardless of the facility's lower limit of normal (LLN).
Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
Left ventricle ejection fraction (LVEF) >= 40% confirmed by echocardiogram (ECHO)/multi gated acquisition (MUGA) scan
Left ventricular ejection fraction (LVEF) >= 40%; 2-dimension (D) transthoracic echocardiogram (ECHO) is the preferred method of evaluation; multi gated acquisition scan (MUGA) is acceptable if ECHO is not available
Left ventricular ejection fraction (LVEF) >= 50% by MUGA (multi gated acquisition) scan or echocardiogram
Baseline multi gated acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= the lower limit of the institutional normal
Left ventricular ejection fraction (LVEF) =< 50% as documented by multi gated acquisition scan (MUGA) or echocardiogram performed within 28 days prior to the first study treatment
Adequate cardiac function as demonstrated by left ventricular ejection fraction (LVEF) of 45% or greater, by multiple gated acquisition (MUGA) or echocardiogram; no ongoing cardiac issues such as uncontrolled arrhythmias or unstable angina or congestive heart failure
Left ventricular ejection fraction (LVEF) > lower limit of normal (LLN) on multi gated acquisition scan (MUGA)
The patient must be free of symptoms of uncontrolled cardiac disease, and must not have compromised cardiac function detected by echocardiogram (ECHO) or by gated cardiac blood flow scan (multi gated acquisition scan [MUGA]) left ventricular ejection fraction [LVEF] > 45%)
Left ventricular ejection fraction (LVEF) >= 45% by multi gated acquisition scan (MUGA)/echocardiogram (ECHO)
Left ventricular ejection fraction ? 50% by echocardiogram or multiple gated acquisition scan.
Cardiac ejection fraction (LVEF) by multiple gated acquisition scan (MUGA) less than the institutional lower limit of normal.
Patients must have a baseline left ventricular ejection fraction (LVEF) measured by multi-gated acquisition scan (MUGA) equal to or greater than the lower limit of normal for the radiology facility and if there are two consecutive MUGAS performed while on trastuzumab from the same radiology facility, there cannot be a decrease in LVEF of > 15% from the original MUGA scan
Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 3 weeks prior to starting study therapy
Left ventricular ejection fraction (LVEF) >= 45% at rest (multi gated acquisition [MUGA] or echocardiogram [ECHO])
Left ventricular ejection fraction (LVEF) < 40% as measured by echocardiogram or multi gated acquisition scan (MUGA)
Left ventricular ejection fraction (LVEF) > 40% as assessed by echocardiogram or multi gated acquisition scan (MUGA)
Left ventricular ejection fraction (LVEF) must be within institutional limits of normal as assessed by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) documented within four weeks prior to first dose of study drug; adequate cardiac reserve ejection fraction (EF) >= 50%
Left ventricular ejection fraction (LVEF) >= 0.4 by multi gated acquisition scan (MUGA) or echocardiogram
Left ventricular ejection fraction (LVEF) =< 55% as determined by multi gated acquisition (MUGA) scan or echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) >= 50% at baseline as determined by either echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
Left ventricular ejection fraction (LVEF) assessment must be performed within 90 days prior to randomization; (LVEF assessment performed by 2-dimensional [2-D] echocardiogram is preferred; however, multi gated acquisition scan [MUGA] scan may be substituted based on institutional preferences); the LVEF must be >= 50% regardless of the cardiac imaging facility's lower limit of normal; note: since the pre-entry LVEF serves as the baseline for comparing subsequent LVEF assessments, it is critical that this baseline study be an accurate assessment; if the baseline LVEF is > 65%, the investigator is encouraged to have the accuracy of the initial LVEF result confirmed and repeat the test if the accuracy is uncertain
Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
Left ventricular ejection fraction (LVEF) greater than or equal to institutional/laboratory lower limit of normal (LLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
Cardiac function: left ventricular ejection fraction >= 40% by multi gated acquisition scan (MUGA) or cardiac magnetic resonance imaging (MRI), or fractional shortening >= 28% by echocardiogram (ECHO)or left ventricular ejection fraction >= 50% by ECHO
Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (ILLN) (by echocardiogram [ECHO] or multi gated acquisition scan [MUGA])
Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal by cardiac echocardiogram (echo) or multi gated acquisition (MUGA) scan within 56 days prior to step 2 registration
Left ventricular ejection fraction (LVEF) that is at or above the lower institutional limits of normal, as assessed by multiple gated acquisition (MUGA) scan or echocardiogram within the 6 weeks prior to registration
Left ventricular ejection fraction (LVEF) >= 45%, preferably by 2-dimensional (D) echocardiogram (echo), or by multiple gated acquisition scan (MUGA); however, patients with LVEF of between 35% and 44% may also be eligible provided that such patients are cleared by a cardiology consultation; in such cases, cardiology will determine whether it is appropriate to perform a cardiac stress test
Left ventricular ejection fraction (LVEF) > 40% (multi gated acquisition scan [MUGA] or echocardiogram) normal per institutional standard
Patients must have a left ventricular ejection fraction (LVEF) >= 50% by echocardiogram or multiple gated acquisition (MUGA) scan within 42 days prior to registration
Patients must not have presence of class III or IV heart failure, according to New York Heart Association classifications, or a known left ventricular ejection fraction of less than 50%; Note: left ventricular ejection fraction (LVEF) evaluation by echocardiogram or multi-gated acquisition scan (MUGA) is not required prior to registration
Abnormal echocardiogram (ECHO) or multi-gated acquisition scan (MUGA) at baseline (left ventricular ejection fraction [LVEF] <40% and shortening fraction <15%). Appropriate correction to be used, if a MUGA is performed.
Abnormal left ventricular ejection fraction (LVEF; <50%) or echocardiogram ECHO or multiple gated acquisition scan (MUGA). [Applies to Phase 1 only; ECHO/MUGA scans are not performed in Phase 2.]
Left ventricular ejection fraction < 50% on echocardiogram or multi-gated acquisition (MUGA)
Left ventricular ejection fraction (LVEF) ?50% measured by multiple-gated acquisition scan (MUGA) or echocardiogram (ECHO)
Left Ventricular Shortening Fraction (LVSF) ? 28% confirmed by echocardiogram (ECHO), or Left Ventricular Ejection Fraction (LVEF) ? 45% confirmed by echocardiogram or Multiple Uptake Gated Acquisition (MUGA).
Has a pre-study echocardiogram or multi-gated acquisition (MUGA) scan with an actual left ventricular ejection fraction of greater than or equal to the institutional lower limit of normal within one month of initiating therapy.
Left ventricular ejection fraction (LVEF) < 50% as determined by Multiple Gated acquisition scan (MUGA) or echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) must be equal to or greater than 50%, as measured by multi gated acquisition (MUGA) scan or echocardiogram
Left ventricular ejection fraction (LVEF) by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan within normal range (according to institutional standards).
Patient has a Left Ventricular Ejection Fraction (LVEF) < 50 % as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO) at screening
For participants who will be receiving CHOP: left ventricular ejection fraction (LVEF) <50% by multiple-gated acquisition (MUGA) scan or echocardiogram
Baseline multi gated acquisition scan (MUGA) or echocardiogram scans with left ventricular ejection fraction (LVEF) of > 50%
Baseline Left Ventricular Ejection Fraction (LVEF) >/= 55 percent (%) measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA)
Left ventricular ejection fraction less than (<) 50% as defined by multiple-gated acquisition (MUGA)
Baseline left ventricular ejection fraction (LVEF) greater than or equal to (>/=) 55 percent (%) measured by echocardiogram (ECHO) or Multiple-Gated Acquisition (MUGA) Scan
Left ventricular ejection fraction (LVEF) >= 50% as assessed by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA) documented =< 28 days prior to registration
Baseline left ventricular ejection fraction LVEF >= 50% as evaluated by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA)
Abnormal echocardiogram (ECHO) or multi-gated acquisition scan (MUGA) at baseline (left ventricular ejection fraction [LVEF] < 55%); appropriate correction to be used if a MUGA is performed
Left ventricular ejection fraction (LVEF) must be equal to or greater than 40%, as measured by multi gated acquisition (MUGA) scan or echocardiogram
Patients who have abnormal echocardiogram (ECHO) or multi-gated acquisition scan (MUGA) at baseline (left ventricular ejection fraction [LVEF] < 50%); appropriate correction to be used if a MUGA is performed
Must have an echocardiogram or multi gated acquisition scan (MUGA) indicating left ventricular ejection fraction (LVEF) >= 50% within 42 days prior to first dose of study drug
Left ventricular ejection fraction (LVEF) no more than 5 absolute percentage points below the institutional standard of normal as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 4 weeks prior to first study drug administration (i.e., if the institutional normal is 50%, subject's LVEF may be as low as 45% to be eligible for the study)
Subjects with New York Heart Association (NYHA) Class III or IV congestive heart failure or left ventricular ejection fraction (LVEF) <40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan within approximately 28 days of C1D1.
Left ventricular ejection fraction (LVEF) below institutional lower limit of normal (LLN) or below 50%, whichever is lower, as determined by echocardiogram or Multi Gated Acquisition Scan (MUGA) scan
Baseline left ventricular ejection fraction (LVEF) >/=55% measured by echocardiogram (ECHO; preferred) or multiple-gated acquisition (MUGA) scans
Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA)
Patient has a Left Ventricular Ejection Fraction (LVEF) < 50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) >= 50% measured by multiple-gated acquisition scan (MUGA) or echocardiogram (ECHO)
Adequate cardiac function, defined as left ventricular ejection fraction ? 40% as assessed by echocardiogram or multiple uptake gated acquisition scan performed within 30 days prior to determination of eligibility
Patients must have adequate cardiac function as demonstrated by normal left ventricular ejection fraction (LVEF) >= the lower limit of normal for the facility on multi gated acquisition (MUGA) scan or echocardiogram (ECHO) within 3 months of enrollment
Subjects with New York Heart Association (NYHA) Class III or IV congestive heart failure or left ventricular ejection fraction (LVEF) <40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan within approximately 28 days of C1D1.
Left ventricular ejection fraction (LVEF) >= 50%, as determined by radionucleoventilugrams (RVG) (multi-gated acquisition-MUGA) or echocardiogram (ECHO) within 28 days prior to initiation of protocol therapy
Left ventricular ejection fraction (LVEF) at least 40% by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) greater or equal to 50% at baseline as determined by either echocardiogram (ECHO) or multi gated acquisition scan (MUGA), or within the institution’s normal limits
Left ventricular ejection fraction (LVEF) >= 50% by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)\r\n* Same method as used at baseline must be use throughout the study, ECHO is the preferred method
Left ventricular ejection fraction (LVEF) by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) >= 45%
Left ventricular ejection fraction >= 50%, as determined by radionuclide ventriculograms (RVG) (multi-gated acquisition scan [MUGA]) or echocardiogram within 60 days prior to initiation of protocol therapy
Left ventricular ejection fraction estimated by multi gated acquisition scan (MUGA) scan or 2-dimensional (2D)-echocardiogram of at least 45% cardiology consult is recommended prior to enrollment if a history of coronary artery disease, congestive heart failure (CHF) with estimated left ventricular ejection fraction (LVEF) of < 50% or clinically significant arrhythmia
Baseline multi gated acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= 50%
Left ventricular ejection fraction (LVEF) >= 45% at rest (multi gated acquisition [MUGA] or echocardiogram [Echo])
Impaired cardiac function (left ventricular ejection fraction [LVEF] < 40%) as assessed by echocardiogram (ECHO) or multi gated acquisition (MUGA) scan
For participants who will be receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP): left ventricular ejection fraction (LVEF) less than (<) 50% by multiple-gated acquisition (MUGA) scan or echocardiogram
Adequate cardiac function, defined by baseline LVEF greater than 50% by Multiple Gated Acquisition (MUGA) scan or echocardiogram.
Left ventricular ejection fraction assessment (echocardiogram or multiple gated acquisition [MUGA] scan) performed within 4 weeks prior to study initiation, showing a left ventricular ejection fraction (LVEF) value >= lower limit of normal (LLN)
Multiple Gated Acquisition (MUGA) or echocardiogram (ECHO) must demonstrate LVEF >/= 45%.
Left ventricular ejection fraction >= 50% by echocardiogram (ECHO) or multi-gated acquisition scan (MUGA)
Left ventricular ejection fraction measured by multi-gated acquisition scan (MUGA) or echocardiogram (ECHO) >= 45%
Baseline multi gated acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= the lower limit of the institutional normal
Left ventricular ejection fraction (LVEF) greater than or equal to 50% on technetium-99m pertechnetate radionuclide cineangiography (multi gated acquisition scan [MUGA]) or echocardiogram
Subjects must have a MUGA scan or echo with LVEF >50%
Left ventricular ejection fraction (LVEF) >= 40% within 28 days prior to registration, evaluated by 2-dimensional (D) transthoracic echocardiogram (ECHO) or, if ECHO is not available, by multi-gated acquisition (MUGA) scan
History of significant cardiovascular disease, even if currently controlled, or who has signs or symptoms suggesting impaired left ventricular function in the judgment of the investigator must have a screening left ventricular ejection fraction (LVEF) evaluation by echocardiogram (ECHO) or multi gated acquisition scan (MUGA); patients with LVEF measurements below local institutional lower limit of normal or less than 50% will not be eligible
Adequate cardiac function (left ventricular ejection fraction [LVEF] >= 40%) as assessed by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) or other similar cardiac imaging performed within 1 month of enrollment
Eligible for SCT with left ventricular ejection fraction (LVEF) >= 50% by multi gated acquisition scan (MUGA) or echocardiogram (ECHO), and diffusing capacity > 50% predicted by pulmonary function testing
Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (LLN) AND at least 50%; LVEF can be assessed by either echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
Left ventricular ejection fraction (LVEF) >= 50% as determined by echocardiogram or multi-gated acquisition scan (MUGA)
LVEF (left ventricular ejection fraction) of 45% or less as determined by MUGA (multi-gated acquisition) or ECHO (Echocardiogram)
Normal cardiac left ventricular ejection fraction (LVEF) by multiple-gated acquisition (MUGA) scan or transthoracic echocardiogram
Left ventricular ejection fraction (LVEF) by echocardiogram or multiple gated acquisition (MUGA) scan ? the lower limit of normal (LLN) for the Institution
Patients have impaired cardiac function or clinically significant cardiac diseases, including any of the following: a) history or presence of serious uncontrolled ventricular arrhythmias or presence of atrial fibrillation; b) clinically significant resting bradycardia (< 50 beats per minute); c) left ventricular ejection fraction (LVEF) assessed by 2-dimensional (D) echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) < 45%; d) pericardial effusion
Left ventricular ejection fraction (LVEF) < 45% as determined by MUGA scan or ECHO
Left ventricular ejection fraction >= 45% by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
Left Ventricular Ejection Fraction (LVEF) < 40% as determined by Multiple Gated Acquisition (MUGA) scan or echocardiogram (ECHO).
Normal left ventricular ejection fraction on screening assessed by transthoracic echocardiogram or multiple gated acquisition (MUGA) scan
Left ventricular ejection fraction (LVEF) determined by 2 dimensional echocardiogram (2D Echo) or multi-gated acquisition scan (MUGA) ? 50% or ? local institutional lower limit normal (LLN) whichever is higher.
Left ventricular ejection fraction (LVEF) at least 40% by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)
Left ventricular ejection fraction as measured by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) should be >= 40%
Left ventricular ejection fraction (LVEF) >= 45% by multi gated acquisition (MUGA) scan or echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) < 50% as determined by multiple gated acquisition scan (MUGA) or echocardiogram (ECHO).
Left ventricular ejection fraction (LVEF) greater than or equal to 50% on technetium-99m pertechnetate radionuclide cineangiography (multi gate acquisition scan [MUGA]) or echocardiogram
Baseline multi gated acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= the lower limit of the institutional normal
Baseline multi gated acquisition (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= 45%
LVEF <45% as determined by MUGA or echo
Baseline multiple gated acquisition (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= 50%
Left ventricular ejection fraction > 40% (multi gated acquisition scan [MUGA] or echocardiogram [echo]) within 28 days of enrollment
Left ventricular ejection fraction (LVEF) >= 50% by multiple gated acquisition scan (MUGA) or cardiac echocardiogram (ECHO), prior for any patient to be treated with R-CHOP
Left ventricular ejection fraction (LVEF) at least 40% by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) be at least >= institutional standard of normal as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 4 weeks prior to first study drug administration
Left ventricular ejection fraction >= 40% by echocardiogram (ECHO)/multi gated acquisition scan (MUGA)
Left ventricular ejection fraction (LVEF) >= 50% by MUGA (multi gated acquisition) scan or echocardiogram
Left ventricular ejection fraction (LVEF) by echocardiogram or multi gated acquisition scan (MUGA) within institutional normal limits
Subjects should have left ventricular ejection fraction (LVEF) >= 50% by echocardiogram or multi gated acquisition (MUGA) scan performed within 4 weeks prior to treatment initiation
LVEF ? 50% by MUGA or ECHO
Left ventricular ejection fraction (LVEF) results must be >= lower limit of normal (LLN) for institution performing based on results from the multi-gated acquisition (MUGA) or echocardiogram (ECHO) done at baseline
Left ventricular ejection fraction (LVEF) >= 45% by multi gated acquisition (MUGA) scan or echocardiogram
Patients must have left ventricular ejection fraction (LVEF) > 50% by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) within 4 weeks prior to registration
Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
Adequate cardiac function as defined by left ventricular ejection fraction (LVEF) >= 50% on echocardiogram or multi-gated acquisition scan (MUGA)
Patients must have adequate cardiac function; left ventricular ejection fraction (LVEF) >= 50% as determined by multi gated acquisition (MUGA) scan or echocardiogram
Left ventricular ejection fraction >= 50% by echocardiogram (ECHO) (preferred) or multi gated acquisition scan (MUGA)
Left ventricular ejection fraction >= institutional lower limit of normal by multi-gated acquisition (MUGA) scan or echocardiogram within 30 days of first protocol treatment
Abnormal echocardiogram (ECHO) or multi-gated acquisition scan (MUGA) at baseline (left ventricular ejection fraction [LVEF] < 55%); appropriate correction to be used if a MUGA is performed
GROUP 2 (trametinib arm): Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
Left ventricular ejection fraction (LVEF) <50 percent (%) as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 4 weeks before receiving the first dose of study drug.
Patients with a history of congestive heart failure (CHF) or are at risk because of underlying cardiovascular disease or exposure to cardiotoxic drugs must have adequate cardiac function as clinically indicated:\r\n* Corrected QT interval (QTC) =< 480 msec\r\n* Shortening fraction of >= 27% by echocardiogram or ejection fraction of >= 50% by gated radionuclide study
Shortening fraction of >= 27% by echocardiogram, or ejection fraction of > 50% by echocardiogram or radionuclide angiogram
Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by gated radionuclide study
Shortening fraction of >= 27% by echocardiogram, or
Patient must have a normal cardiac ejection fraction by pretreatment multigated acquisition scan (MUGA) or echocardiogram within 4 weeks prior to registration (resting ejection fraction >= 40% or >= 5% increase with exercise), shortening fraction by echocardiogram >= 24%, or to within the normal range of values for the institution
Shortening fraction of >= 27% by echocardiogram OR ejection fraction of >= 50% by radionuclide angiogram
Shortening fraction >= 27% by echocardiogram, or ejection fraction >= 50% by gated radionuclide study \r\n* Patients must have an electrocardiogram (EKG) fewer than 6 days prior to enrollment on the dasatinib arm; patients who have had cardiac assessments by echocardiogram or radionuclide scan at the beginning of induction do not need to have these repeated prior to study entry; correct QT interval (QTc) < 450 msec on baseline electrocardiogram as measured by the Frederica or Bazett formula\r\n* No major conduction abnormality (unless a cardiac pacemaker is present)
Shortening fraction of >= 27% by echocardiogram, or
Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by radionuclide angiogram
Shortening fraction of >= 27% by echocardiogram, or
Shortening fraction of >= 27% by echocardiogram
Ejection fraction of >= 50% by radionuclide angiogram or echocardiogram
Shortening fraction of >= 27% by echocardiogram (for patients on doxorubicin-containing regimens [Groups C, D, E, and F]), or
Adequate Cardiac Function defined as: Shortening fraction of ? 27% by echocardiogram, or Ejection fraction of ? 50% by radionuclide evaluation or echocardiogram.
Shortening fraction of >= 27% by echocardiogram (while not receiving medications for cardiac function), or
Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by gated radionuclide study
Patients must have adequate cardiac function as defined as:\r\n* Shortening fraction of ? 27% by echocardiogram, or\r\n* Ejection fraction of ? 50% by radionuclide angiogram
Shortening fraction > 28% by echocardiogram or Ejection Fraction of > 50 % by multigated acquisition (MUGA)
Within 4 weeks prior to study enrollment: Shortening fraction of >= 27% by echocardiogram OR
Shortening fraction >= 28% by echocardiogram OR ejection fraction of >= 50 % by multigated acquisition (MUGA)
Shortening fraction of >= 27% by echocardiogram, OR
Ejection fraction of >= 50% by gated radionuclide study/echocardiogram
Shortening fraction >= 28% by echocardiogram or ejection fraction of >= 50 % by multigated acquisition (MUGA)
Shortening fraction of >= 27% by echocardiogram OR
Shortening fraction > 28% by echocardiogram or ejection fraction of > 50 % by MUGA
Shortening fraction > 28% by echocardiogram or
Ejection fraction > 50% by echocardiogram or radionuclide study
Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by gated radionuclide study within 7 days prior to enrollment
Echocardiogram must have a shortening fraction or an ejection fraction greater than institutional lower limit of normal for age and gender; echocardiogram must be obtained while patient is not receiving cardiotropic medications (eg., pressors or afterload reducers)
Adequate cardiac function defined as: normal 12 lead electrocardiogram (EKG) with corrected QT interval (QTc) < 450 msec, and either shortening fraction of >= 28% by echocardiogram and qualitatively normal left ventricular function, or ejection fraction of >= 55% by echocardiogram
Patient must have normal cardiac function documented by ejection fraction (> 55%) documented by echocardiogram or radionuclide MUGA evaluation or fractional shortening ( > 27%) documented by echocardiogram and EKG must demonstrate no abnormality severe enough to justify cardiac medications and baseline QTc interval less than or equal to 450 msecs
Ejection fraction >= 45% on echocardiogram
Shortening fraction of >= 27% by echocardiogram, or ejection fraction (left ventricular ejection fraction [LVEF]) >= 50% by gated radionuclide study
Shortening fraction > 24% by echocardiogram, or ejection fraction > 30% by radionuclide angiogram
Shortening fraction of >= 27% by echocardiogram
Normal ejection fraction (>= 55%) documented by either echocardiogram or radionuclide MUGA evaluation OR normal fractional shortening (>= 27%) documented by echocardiogram
Shortening fraction of >= 27% by echocardiogram, or
Ejection fraction of >= 50% by radionuclide angiogram or echocardiogram
Shortening fraction >= 28% by echocardiogram or ejection fraction >= 50% by echocardiogram or radionuclide study
Shortening fraction of >= 27% by echocardiogram, or
Ejection fraction of >= 50% by radionuclide angiogram or echocardiogram
Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by radionuclide angiogram
Shortening fraction >= 27% by echocardiogram, or
Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by gated radionuclide study
Shortening fraction of >= 27% by echocardiogram or ejection fraction of >= 50% by gated radionuclide study
Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by gated radionuclide study
Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by gated radionuclide study
For patients on Part B: shortening fraction of >= 27% by echocardiogram or ejection fraction of >= 50% by gated radionuclide study
Shortening fraction of >= 27% by echocardiogram (ECHO) OR
Shortening fraction >= 27% by echocardiogram
Ejection fraction > 50% on echocardiogram
Ejection fraction >= 50% by echocardiogram
Shortening fraction >= 28% on screening echocardiogram
Shortening fraction greater than or equal to 28% by echocardiogram OR
Patients must have a shortening fraction greater than or equal to 27% by echocardiogram, OR ejection fraction greater than or equal to 50% by radionuclide angiogram (multigated acquisition [MUGA])
Adequate cardiac function defined as shortening fraction of ? 27% by echocardiogram or ejection fraction ? 45% by gated radionuclide study.
Ejection fraction >= 50% by echocardiogram
NON-PROGRESSED DIPG (STRATUM 2): Left ventricular ejection fraction >= 50 by gated radionuclide study OR shortening fraction of >= 27% by echocardiogram
Shortening fraction of >= 27% by echocardiogram, or
Cardiac Function: Patient must have a shortening fraction (SF) of > 27% or an ejection fraction (EF) of > 50% by echocardiogram or MUGA scan.
Shortening fraction of >= 27% by echocardiogram
Shortening fraction greater than or equal to 28% by echocardiogram OR
Shortening fraction of >= 27% by echocardiogram or ejection fraction >= 45% by gated radionuclide study
Shortening fraction >= 27% by echocardiogram or
Shortening fraction of >= 25% by echocardiogram
Must have electrocardiogram (EKG) with corrected QT (QTc) interval < 450 msec and Echocardiogram with shortening fraction >= 27% or ejection fraction > 50%
Shortening fraction greater than or equal to 27% by echocardiogram; corrected QT interval =< 450 milliseconds
Shortening fraction of >= 27% by echocardiogram, or if shortening fraction abnormal, ejection fraction of >= 55% by gated radionuclide study or echocardiogram; note: the echocardiogram or gated radionuclide study must be performed within 4 weeks prior to enrollment
Shortening fraction on echocardiogram > 28%
Ejection fraction of < 50% (by radionuclide angiogram or echocardiogram) or shortening fraction of < 25% (by echocardiogram)\r\n* Note: for instances where both are reported, and one is below the threshold, the site will have the option to re-measure it centrally at the core lab
Cardiac function: Ejection fraction at rest ? 45.0% or shortening fraction of ? 27.0% by echocardiogram or radionuclide scan (MUGA).
Shortening fraction > 27% by echocardiogram, or
Ejection fraction of > 47% by radionucleotide angiogram or echocardiogram
Shortening fraction of > 25% by echocardiogram, or
Ejection fraction of > 40% by radionuclide angiogram or echocardiogram
Normal baseline cardiac ejection fraction >= 50%
Ejection fraction of >= 50% by gated radionuclide study
Ejection fraction of >= 50%
Ejection fraction of >= 50% by radionuclide angiogram
Ejection fraction of >= 50% by radionuclide angiogram
Ejection fraction of >= 50% by radionuclide angiogram (for patients on doxorubicin-containing regimens (Groups C, D, E, and F)
Patients with angina, a cardiac ejection fraction < 50%, or ischemic heart disease are not eligible
All included patients must have normal cardiac function as defined by an ejection fraction of >= 50% and no decrease in wall motion by echocardiogram
Ejection fraction of >= 50% by gated radionuclide study (while not receiving medications for cardiac function)
All included subjects must have normal cardiac function as defined by an ejection fraction of > 50% by echocardiogram
Cardiac ejection fraction < 30% (or, if unable to obtain ejection fraction, shortening fraction < 26%) on multiple-gated acquisition (MUGA) scan or cardiac echocardiogram (echo), symptomatic coronary artery disease, or other cardiac failure requiring therapy; patients with a history of, or current cardiac disease should be evaluated with appropriate cardiac studies and/or cardiology consult; patients with a shortening fraction of < 26% must be seen by cardiology for approval
Cardiac function: Ejection fraction > 40%
Ejection Fraction >= 45%
Normal ejection fraction (echocardiogram [ECHO]) >= 53% (if a range is given then the upper value of the range will be used) or cardiac MRI
Ejection fraction >= 45%
Cardiac ejection fraction < 45%
Cardiac ejection fraction < 35%
Within 4 weeks prior to study enrollment: Ejection fraction of >= 50% by radionuclide angiogram
Cardiac ejection fraction >= 50% as determined by screening echocardiogram
Baseline cardiac ejection fraction must be >= 40 %.
Cardiac ejection fraction of >= 45%
Cardiac ejection fraction ? 50%, no evidence of pericardial effusion, and no clinically significant arrhythmias
No uncontrolled or severe cardiac disease. Baseline ejection fraction (by nuclear imaging or echocardiography) must by ? 50%
Cardiac ejection fraction of >= 45%
Ejection fraction of >= 55% by gated radionuclide study
Known cardiac ejection fraction of > or = 45% within the past 3 months
Ejection fraction > 45%
Normal cardiac ejection fraction (greater than or equal to 50% by echocardiography) and no evidence of hemodynamically significant pericardial effusion as determined by an echocardiogram within 4 weeks of the start of the treatment protocol
History of congestive heart failure and cardiac ejection fraction =< 40%
Cardiac ejection fraction ? 50%, no evidence of pericardial effusion as determined by an ECHO, and no clinically significant ECG findings
Cardiac ejection fraction >= 50%
Cardiac ejection fraction at rest must be >= 40%
Cardiac ejection fraction >= 45% by echocardiogram (ECHO)
Ejection fraction less than 40% by echocardiography
Participants must have normal cardiac ejection fraction (per label, as defined as institutional normal)
Ejection fraction >= 40%
Normal cardiac ejection fraction (greater than or equal to 55% by echocardiography) and no evidence of hemodynamically significant pericardial effusion as determined by an echocardiogram within 4 weeks of the start of the treatment protocol
Cardiac ejection fraction greater than or equal to 50% by echocardiogram
Baseline ejection fraction must be >= 40%
Baseline test of ejection fraction must be >= 50%
Normal cardiac function must be documented within 90 days prior to registration; result of ejection fraction must be above the normal limit of the institution
Ejection fraction < 30%, or uncontrolled cardiac failure
Ejection fraction > 50%
Known cardiac ejection fraction < 50%
Known cardiac ejection fraction of >= 45% within the past 6 months
Patients with significant lung disease, an ejection fraction less than 40%, or a resting heart rate less than 60/min will not be enrolled
Ejection fraction >= 35%
Cardiac ejection fraction =< 50%
Adequate cardiac reserve with a cardiac ejection fraction within the lower limit of facility normal by MUGA, or 50% by echocardiogram
Ejection fraction >= 45%
Cardiac: ejection fraction > 45%
Clinically significant heart disorders including an ejection fraction of < 50%
Cardiac ejection fraction ? 50%. If between 40-49% a cardiology consult is required
Cardiac ejection fraction > 30%
Cardiac ejection fraction less than 40%
Known cardiac ejection fraction of >= 45% within the past 3 months
Cardiac ejection fraction >= 45% or within institutional normal limits; a nuclear medicine gated blood pool examination is preferred; a two-dimensional (2-D) echocardiogram (ECHO) scan is acceptable if a calculated ejection fraction is obtained and follow-up measurement of the cardiac ejection fraction will also be performed by echocardiography; measurement of cardiac ejection fraction should be within two weeks prior to receiving treatment\r\n* NOTE: when a multi gated acquisition scan (MUGA) or echocardiogram cannot be obtained due to weekend or holiday, then patients may be enrolled provided there is no history of significant cardiovascular disease and a measurement of cardiac ejection fraction will be performed within 5 days of study enrollment
Patients must have a cardiac ejection fraction of >= 40%, or within institutional normal limits; a nuclear medicine gated blood pool examination is preferred; a 2-D ECHO scan is acceptable if a calculated ejection fraction is obtained and follow-up measurement of the cardiac ejection fraction will also be performed by echocardiography; measurement of cardiac ejection fraction should be within two weeks prior to allogeneic transplantation
Cardiac ejection fraction >= 45%
Ejection fraction >= 47% by radionuclide angiogram
Cardiac ejection fraction has to be >= 50%
Normal cardiac ejection fraction (greater than or equal to 50% by echocardiography) and no evidence of hemodynamically significant pericardial effusion as determined by an echocardiogram within 6 weeks of the start of the treatment protocol
Patients must not have ejection fraction decrease > 10% from baseline (as determined by ECHO) or other ejection fraction decrease accompanied by other clinical signs/symptoms of New York Heart Association (NYHA) class III or IV heart failure, measured within 28 days prior to registration; if any question exists regarding individual patient eligibility in this situation, contact the study chair for determination
Ejection fraction >= 50%
Cardiac ejection fraction < 30% or, if unable to obtain ejection fraction, shortening fraction of < 26%) on multi-gated acquisition (MUGA) scan or cardiac echo, symptomatic coronary artery disease, other cardiac failure requiring therapy; patients with a history of, or current cardiac disease should be evaluated with appropriate cardiac studies and/or cardiology consult; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologist
Patients must not have symptomatic congestive heart failure, coronary artery disease, cardiomyopathy, or uncontrolled arrhythmias; either an echocardiogram or MUGA scan with an ejection fraction >= 45% must be obtained within 14 days prior to registration; (the same scan that was used during induction registration must be used for consolidation registration); the ejection fraction must not have dropped >= 10% from the baseline ejection fraction; if patient has had symptoms suggestive of ischemia or congestive heart failure after that cardiac evaluation was done, a repeat study must be obtained prior to registration
Cardiac ejection fraction of >= 40% as measured by resting echocardiogram, with no significant pericardial effusion
Ejection fraction must be >= 50%
Cardiac ejection fraction >= 50%
Pre-existing known cardiovascular abnormalities as defined by any one of the following: \t\r\n* Congestive heart failure \r\n* Clinically significant hypotension \r\n* Cardiac ischemia, or symptoms of coronary artery disease\r\n* Presence of cardiac arrhythmias on electrocardiogram (EKG) requiring drug therapy\r\n* Ejection fraction < 45% (echocardiogram or MUGA), although any patient with an ejection fraction between 45-49% must receive clearance by a cardiologist to be eligible for Step II of the trial
Pre-existing known cardiovascular abnormalities as defined by any one of the following: \t\r\n* Congestive heart failure \r\n* Clinically significant hypotension \r\n* Cardiac ischemia, or symptoms of coronary artery disease\r\n* Presence of cardiac arrhythmias on EKG requiring drug therapy\r\n* Ejection fraction < 45%, although any patient with an ejection fraction between 45-49% must receive clearance by a cardiologist to be eligible for Step II of this trial
Ejection fraction >= 50% by ECHO or gated radionuclide study
Cardiac ejection fraction ? 50% and no clinically significant ECG findings
Cardiac ejection fraction >= 50%
Normal cardiac ejection fraction of > 45%
Cardiac history of CHF requiring treatment or Ejection Fraction less than or equal to 50% or chronic stable angina;
Cardiac ejection fraction < 45%
Ejection fraction >= 45%
Cardiac ejection fraction >= 45%
Cardiac ejection fraction > 40%
Ejection fraction > 40%
Cardiac ejection fraction >= 40%
Cardiac ejection fraction ? 50% by echocardiography or MUGA
Ejection fraction >= 35% (within 6 weeks prior to study enrollment)
Cardiac ejection fraction > 45%
Normal cardiac ejection fraction and no evidence of pericardial effusion as determined by an echocardiogram
Cardiac ejection fraction < 40%; ejection fraction is required if age > 50 years or there is a history of prior transplant, anthracycline exposure or history of cardiac disease; and poorly controlled hypertension despite multiple antihypertensives
Cardiac ejection fraction (EF) < 40% on multi-gated acquisition (MUGA) scan or cardiac echocardiogram (echo) (or if unable to obtain ejection fraction, shortening fraction of < 26%); patients with active or a history of cardiac disease should be evaluated with appropriate cardiac studies and/or consult; ejection fraction is required if age > 50 years or there is a history of anthracyclines or history of cardiac disease; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologist
Known ejection fraction < 50%.
Ejection fraction equal or above 40%
Cardiac ejection fraction within normal limits as measured by echocardiogram
Ejection fraction of >= 50% by radionuclide angiogram
Ejection fraction < 50%
Cardiac ejection fraction ?50% by ECHO or MUGA
Ejection fraction of >= 50% by radionuclide angiogram
Ejection fraction >= 50% by radionuclide evaluation
Cardiac ejection fraction >= 50% without evidence of congestive heart failure (CHF)
Cardiac ejection fraction ?50% by ECHO or MUGA
Patients with poor cardiac function as defined by an ejection fraction < 40% are excluded (only for patients enrolled on second phase of protocol for leukapheresis)
Abnormal baseline cardiac function defined as an ejection fraction of less than 55%
Cardiac ejection fraction < 50 (using motion [M]-Mode if assessment is done by echocardiogram [ECHO])
Cardiac ejection fraction >= 40%
Cardiac ejection fraction > 40%
Adequate cardiac function defined as an ejection fraction of at least 45%
A normal ejection fraction, as defined by the participant’s institution; only limited echocardiograms (ECHOs) will be used as cardiac evaluation; no other tests are allowed; ECHO is to be done only in HLA-A2 positive participants; If ECHO has been done within 30 days prior to randomization and results showing a normal ejection fraction have been obtained prior to randomization, an additional ECHO is not needed at baseline
Patients with an ejection fraction < 45% assessed by MUGA or ---ECHO within 28 days prior to starting study cycle 1 (of midostaurin or control group)
Ejection fraction at rest >= 50%
Cardiac function: ejection fraction > 40%
Cardiac function: Ejection fraction at rest ? 45%
Patients must have normal cardiac ejection fraction
Participants must have normal cardiac ejection fraction
Cardiac ejection fraction ? 50%, no evidence of pericardial effusion as determined by an ECHO, and no clinically significant ECG findings
Cardiac ejection fraction >50% (by echocardiogram or MUGA) within 15 days of enrollment
The patient’s estimated cardiac ejection fraction is < 50% by echocardiogram or MUGA
Patient has a cardiac ejection fraction <50%
Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multigated acquisition scan (MUGA) within 30 days of day 1 of study
Patients must have an echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 42 days prior to registration with a cardiac ejection fraction >= 45%
Left ventricular ejection fraction >= 50%, as determined by multigated acquisition (MUGA) or echocardiogram within 30 days prior to protocol registration
Patients must have left ventricular ejection fraction (LVEF) >= 50 as measured by echocardiogram or multigated acquisition scan (MUGA)
Patients with an ejection fraction < 50% assessed by multigated acquisition scan (MUGA) or echocardiogram (ECHO) scan within 7 days of day 1
Left ventricular ejection fraction (LVEF) must be within institutional limits of normal as assessed by echocardiogram or multigated acquisition scan (MUGA) documented within 28 days prior to first dose of study drug
Participants with a history of chronic heart failure or significant cardiovascular disease must have an echocardiogram or multigated acquisition scan indicating left ventricular ejection fraction greater than or equal to 45% within 28 days prior to the first dose of study drug.
Left ventricular ejection fraction (LVEF) >= 50% by 2-dimensional (2D) echocardiogram (ECHO) or multigated acquisition (MUGA) scan; timeline: within 4 weeks prior to enrollment
Left ventricular ejection fraction; LVEF >= 40% (by echocardiogram or multigated acquisition scan [MUGA] testing)
For Part F (LY2835219 + trastuzumab):The participant must have received at least 1 chemotherapy regimen for metastatic disease and may be receiving ongoing therapy with trastuzumab. The participant must have an estimated left ventricular ejection fraction within the normal range by either echocardiogram or multigated acquisition (MUGA) scan
Patients with symptomatic left ventricular dysfunction or baseline left ventricular ejection fraction (LVEF) my multigated acquisition scan (MUGA) or echocardiogram (ECHO) of =< 50% are not eligible
Left ventricular ejection fraction (LVEF) >= 50% (determined by echocardiogram or multigated acquisition scan) within 42 days of treatment
Left ventricular ejection fraction (LVEF) ? 50% by echocardiogram (echo) or multigated acquisition (MUGA) scan within 28 days before day 1 of study
Have a left ventricular ejection fraction (LVEF) >45% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan
On echocardiogram, documented left ventricular ejection fraction > 45%; patients may instead have a multigated acquisition (MUGA) scan instead of transthoracic echocardiogram (TTE).
ENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Left ventricular ejection fraction (LVEF) >= 50% as determined by echocardiogram or multigated acquisition scan (MUGA)
Left ventricular cardiac ejection fraction of ?45% by echocardiogram or multigated acquisition (MUGA) scan
Left ventricular ejection fraction >= 45% by multigated acquisition scan (MUGA) or echocardiogram
Left ventricular ejection fraction >= 40% by 2 dimensional (D) echocardiogram (ECHO) or multigated acquisition (MUGA) scan, or left ventricular shortening fraction >= 20% by ECHO for patients receiving MAC, RIC or RIC-MMF, or LVEF > 30%; if the patient has radiologic evidence of aortic, renal, or coronary artery vasculitis, LVEF >= 30% for patients receiving IOC
Left ventricular ejection fraction (LVEF) must be equal to or greater than 50%, as measured by multigated acquisition (MUGA) scan or echocardiogram
Ejection fraction measured by echocardiogram or multigated acquisition (MUGA) >= 50%
Baseline multigated acquisition scan (MUGA) or echocardiogram (ECHO) done only in subjects with prior doxorubicin exposure. The test must demonstrate left ventricular ejection fraction (LVEF) >= the lower limit of the institutional normal
Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) as assessed by either multigated acquisition (MUGA) scan or echocardiogram (ECHO)
Have current or a history of congestive heart failure New York Heart Association (NYHA) class 3 or 4, or any history of documented diastolic or systolic dysfunction (left ventricular ejection fraction [LVEF] < 40%, as measured by multigated acquisition [MUGA] scan or echocardiogram)
Ejection fraction < 50% on screening echocardiography (ECHO) or multigated acquisition scan (MUGA).
Cardiac ejection fraction within institutional normal limits by either multigated acquisition scan (MUGA) or echocardiogram (ECHO) at baseline
If the participant is to be enrolled in the doxorubicin combination arm, a left ventricular dysfunction (LVEF < 50%) or shortening fraction of <27% by echocardiogram (either multigated acquisition [MUGA] or echocardiogram [ECHO] are required, not both).
Must be hemodynamically stable at the time of ET190L1-ARTEMIS T cell administration and have left ventricular ejection fraction (LVEF) ? 45% confirmed by echocardiogram or multigated acquisition scan (MUGA) scan
Within 4 weeks before enrollment: Left ventricular ejection fraction (LVEF) > 45% by multigated acquisition (MUGA) or rest echocardiogram (ECHO)
Adequate cardiac function, defined as left ventricular ejection fraction (LVEF) of >= 50% as assessed by echocardiogram or multigated acquisition (MUGA) scan, or LVEF of 45-49% and clearance by a cardiologist
Left ventricular ejection fraction (LVEF) ? 55% at rest (multigated acquisition [MUGA] scan or echocardiogram [Echo])
Left ventricular ejection fraction greater than (>) 50% as measured by ECHO or MUGA scan within 4 weeks before receiving the first dose of study drug.
Has left ventricular ejection fraction (LVEF) < 45% by either echocardiogram (ECHO) or multigated acquisition (MUGA) scan.
Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiography (ECHO) or multigated acquisition (MUGA)
Cardiac echocardiogram, stress test, or multigated acquisition (MUGA) within past 6 months with demonstrated left ventricular ejection fraction (LVEF) > 50%
Left ventricular ejection fraction >= 50% measured by multigated acquisition (MUGA) scan or echocardiogram
If a patient has received anthracycline chemotherapy after prior enrollment on PLAT-02, they must have an echocardiogram to demonstrate shortening fraction > 28% or multigated acquisition scan (MUGA) to demonstrate ejection fraction of > 50%; the echocardiogram or MUGA can be done at any time following the anthracycline (does NOT need to be within 48 hours of the T cell infusion)
(For cohort B): Baseline multigated acquisition (MUGA) or echocardiogram showing left ventricular ejection fraction (LVEF) >= 50% within 6 weeks prior to initiation of NACT
Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (ECHO) or multigated acquisition scan (MUGA)
Impaired cardiac function (left ventricular ejection fraction [LVEF] < 40%) as assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) scan
Left ventricular ejection fraction (LVEF) >= 50% by transthoracic echocardiogram or multigated acquisition scan (MUGA)
Patients have left ventricular ejection fraction (LVEF) >= 50% by multigated acquisition scan (MUGA) or echocardiogram before study randomization
Baseline left ventricular ejection fraction of at least 40% by multigated acquisition (MUGA) or echocardiography (ECHO)
Left ventricular ejection fraction (LVEF) at rest >= 40%; for patients aged < 13 years, shortening fraction (SF) >= 26% by echocardiogram or LVEF by multigated acquisition scan (MUGA) may be used
Left ventricular ejection fraction (LVEF) < 50% as determined by multigated acquisition (MUGA) scan or electrocardiogram (ECHO), or uncontrolled hypertension (refer to World Health Organization-International Society of Hypertension [WHO-ISH] guidelines)
Adequate cardiac function as defined by the following:\r\n* Left ventricular ejection fraction (LVEF) >= 50% as determined by a multigated acquisition (MUGA) scan or echocardiogram\r\n* Corrected QT interval (QTc) interval =< 480 ms (preferably the mean from triplicate electrocardiogram [ECG’s])
Left ventricular ejection fraction (LVEF) lower limit of normal (LLN) as assessed by either multigated acquisition (MUGA) scan or echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multigated acquisition scan (MUGA)
Ejection fraction of > 40% by multigated acquisition (MUGA) or echocardiogram
Ejection fraction measured by echocardiogram or multigated acquisition scan (MUGA) >= 50%
Cardiac ejection fraction >= 40% (by either echocardiogram [ECHO] or multigated acquisition [MUGA])
If prior history of ischemic heart disease or exposure to 200 mg/m^2 of doxorubicin, patients must have a measured ejection fraction (either by multigated acquisition scan [MUGA], echocardiogram [ECHO], stress test, or ventriculography) of at least 45%
Shortening fraction > 28% by echocardiogram or an ejection fraction > 50% by multigated acquisition scan (MUGA)
Cardiac ejection fraction > 50% (for HER2+ patients) as assessed by echocardiogram, multigated acquisition (MUGA) scan, or cardiac magnetic resonance imaging (MRI)
Left ventricular ejection fraction (LVEF) of 50% or above, by multigated acquisition scan (MUGA) or echocardiogram
If the research participant is to undergo leukapheresis, he/she must have ejection fraction measured by echocardiogram or multigated acquisition scan (MUGA) > 45% (within 6 weeks of time of screening)
Ejection fraction >=40% by transthoracic echocardiogram or radionuclide ventriculogram, i.e. multigated acquisition (MUGA) scan
Left ventricular ejection fraction (LVEF) greater than or equal to 50% as determined by a multigated acquisition (MUGA) scan or echocardiogram (Phase II only)
Patients must have adequate cardiac function (left ventricular ejection fraction [LVEF]) >= 50% as determined by a multigated acquisition (MUGA) scan or echocardiogram
Left ventricular ejection fraction (EF) > 40% by echocardiogram, multigated acquisition scan (MUGA), or cardiac magnetic resonance (MR)
Left ventricular ejection fraction (LVEF) >= 40% as assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) or other similar cardia imaging performed within 1 month of treatment
Have a left ventricular ejection fraction (LVEF) >45% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan
Patients with a cardiac ejection fraction (as measured by either multigated acquisition scan [MUGA] or echocardiogram) < 40% are excluded
Left ventricular ejection fraction (LVEF) assessment must be performed within 6 weeks prior to randomization; (LVEF assessment performed by echocardiogram is preferred; however, multigated acquisition scan (MUGA) scan may be substituted based on institutional preferences); the LVEF must be >= 55% regardless of the cardiac imaging facility's lower limit of normal
Left ventricular ejection fraction (LVEF) >= 50% measured by multigated acquisition (MUGA) scan, echo, or stress test study with myocardial perfusion imaging
Left ventricular ejection fraction (LVEF) >= 45% as determined by a multigated acquisition (MUGA) scan or echocardiogram, and QTc interval =< 480ms
Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (ECHO) or multigated acquisition (MUGA)
To be performed within 28 days prior to day 1 of protocol therapy: Left ventricular ejection fraction >= 50% as determined by multigated acquisition (MUGA) scan or echocardiogram
Left ventricular ejection fraction (LVEF) >= 50% calculated by echocardiogram (ECHO) or multigated acquisition scan (MUGA)
Ejection fraction (EF) >= 50% by multigated acquisition (MUGA) or echocardiography (ECHO) within 4 weeks prior to first dose of study treatment
Adequate cardiac function:\r\n* Left ventricular ejection fraction (LVEF) >= 50% as determined by multigated acquisition (MUGA) scan or echocardiogram (echo)\r\n* Corrected QT (QTc) interval =< 480 ms
Left ventricular ejection fraction (LVEF) >= 45% at rest (multigated acquisition scan [MUGA] or echocardiogram [Echo])
Patients must have multigated acquisition (MUGA)/echocardiogram performed within 28 days prior to sub-study registration
Ejection fraction (EF) measured by two-dimensional echocardiogram (2D-ECHO) or multigated acquisition scan (MUGA) scan of >= 45%
Baseline multigated acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= 45%
Left ventricular ejection fraction (LVEF) >= 50% by echocardiogram (ECHO) or multigated acquisition scan (MUGA); same method as used at baseline must be use throughout the study, ECHO is the preferred method
Left ventricular ejection fraction (LVEF) by echocardiogram (ECHO) or multigated acquisition (MUGA) > 40%
Left ventricular ejection fraction >= 45% by multigated acquisition scan (MUGA) or echocardiogram (ECHO), fractional shortening >= 28% by ECHO
Left ventricular ejection fraction at or above institutional lower limit of normal (obtained within 8 weeks of registration by multigated acquisition [MUGA] scan or echocardiogram; the same test performed at baseline should be repeated after every 3 cycles of therapy)
Cardiac ejection fraction at or above the lower limit of normal as measured by multigated radionuclide angiography (MUGA) scans or echocardiogram documented =< 3 months prior to registration
Patients must have a left ventricular ejection fraction >= lower limit of normal by echocardiogram (ECHO) or multigated acquisition scan (MUGA)
Have left ventricular ejection fraction by multigated acquisition scan (MUGA) scan or 2D-ECHO within normal limits for the institution
Patients with a known history of congestive heart failure or cardiac ejection fraction < 50% (or less than institutional normal limits); echocardiogram (ECHO) or multigated acquisition scan (MUGA) is not required prior to enrollment; for patients assigned to the chemotherapy arm, an ECHO or MUGA should be done within 6 months of day 1 of gemcitabine-docetaxel treatment\r\n* Patients who enroll on study and are randomized to Regimen I (chemotherapy ) and then are found on baseline ECHO or MUGA to have cardiac ejection fraction < 50% or below institutional normal will remain ON study; such patients will receive gemcitabine + docetaxel for 4 cycles but will NOT receive any doxorubicin treatment; they will continue treatment follow-up as outlined for all patients assigned to Regimen I
Left ventricular ejection fraction >= lower limit of normal as assessed by echocardiogram or multigated acquisition scan
Patients who received prior therapy with anthracyclines should have a baseline multigated acquisition scan (MUGA) or echocardiogram (echo) with a normal ejection fraction within 28 days prior to randomization
left ventricular ejection fraction (LVEF) < 45% as determined by multigated acquisition (MUGA) scan or echocardiography (ECHO).
Patients must have a left ventricular ejection fraction (LVEF) >= 50% by (either multigated acquisition [MUGA] or 2-dimensional [2-D] echocardiogram) within 28 days of registration
Left ventricular ejection fraction (LVEF) >= 40% as confirmed by echocardiogram (ECHO)/multigated acquisition (MUGA)
Patient must have adequate cardiac function (left ventricular ejection fraction [LVEF] >= 50% as determined by a multigated acquisition [MUGA] scan or echocardiogram; and corrected QT [QTc] interval =< 480 ms by Fridericia’s formula [QTcF])
Cardiac left ventricular function with resting ejection fraction >50% as determined by echocardiogram (ECHO) or multigated acquisition scan (MUGA).
Patients older than 70 years of age should have left ventricular ejection fraction within ULN by multigated acquisition (MUGA) or 2-dimensional (2D) echocardiogram
Left ventricular ejection fraction (LVEF) < 50% as determined by a multigated acquisition (MUGA) scan or echocardiogram
Left ventricular ejection fraction (LVEF) defined by multigated acquisition (MUGA) or echocardiogram which is below the institutional lower limit of normal prior to starting study treatment
Has a left ventricular ejection fraction (LVEF) within the normal institutional range (or >= 50%) based on an echocardiogram (ECHO) or multigated acquisition scan (MUGA), completed within 4 weeks prior to day one of treatment
Baseline Left ventricular ejection fraction (LVEF) >=50% as measured by Echocardiogram (ECHO) or Multigated acquisition (MUGA) and above the testing institution's lower limit of normal
Left ventricular ejection fraction (LVEF) >= 40% on 2-dimentional (2-D) transthoracic echocardiogram (ECHO); multigated acquisition scan (MUGA) is acceptable
Adequate cardiac function defined as left ventricular ejection fraction (LVEF) >= 40%\r\n* NOTE: 2-dimensional (2-D) transthoracic echocardiogram (ECHO) is the preferred method of evaluation\r\n* Multigated acquisition scan (MUGA) is acceptable if ECHO is not available
Left ventricular ejection fraction (LVEF) must be within institutional limits of normal as assessed by echocardiogram or multigated acquisition scan (MUGA) documented within 4 weeks prior to first dose of study drug.
Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multigated acquisition scan (MUGA)
Have a 12-lead electrocardiogram (ECG) and echocardiogram (ECHO) or multigated acquisition (MUGA) scan performed by the investigator or other qualified person to evaluate cardiac function prior to enrollment in the study
Left ventricular ejection fraction >= 50%, as determined by radionuclide ventriculogram (RVG) (multigated acquisition [MUGA]) or echocardiogram (ECHO) within 60 days prior to initiation of protocol therapy
Patient must have a left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multigated acquisition (MUGA) within 28 days prior to registration
Normal left ventricular ejection fraction on multigated acquisition scan (MUGA) or echocardiogram within the past 1 year prior to registration for patients with history of congestive heart failure and/or coronary disease requiring medications other than aspirin, or known prior exposure to anthracycline chemotherapy
Ejection fraction by echocardiogram (ECHO) or multigated acquisition scan (MUGA) of >= 40% performed
Adequate cardiac function (left ventricular ejection fraction [LVEF] > 40%) as assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) scan performed within 1 month of treatment
Ejection fraction >= 45% as determined by transthoracic echocardiogram or multigated acquisition scan (MUGA)
Cardiac ejection fraction >= lower limit of normal as determined by 2-dimensional (D) echocardiogram (echo) or multigated acquisition (MUGA) scan according to institutional standards
Cardiac ejection fraction, as assessed by either multigated acquisition (MUGA) scan or echocardiogram, greater than or equal to 50%, within 28 days prior to registration
Left ventricle ejection fraction (LVEF) >= 40%; 2-dimensional (D) transthoracic echocardiogram (ECHO) is the preferred method of evaluation; multigated acquisition scan (MUGA) is acceptable if ECHO is not available
Left ventricular ejection fraction >= the lower limit of normal by echocardiogram (ECHO) or multigated acquisition scan (MUGA)
Left ventricular ejection fraction > 45% by either multigated acquisition scan (MUGA) or 2-dimensional (2-D) echocardiogram (echo), obtained within 28 days of enrollment; patients who have a prior cumulative anthracycline dose greater than 450 mg/m^2 will also have a cardiology consult to determine if further anthracycline administration is an absolute contraindication in patients who may require induction chemotherapy with EPOCH-F
Ejection fraction (EF) of at least >= 40% by multigated acquisition (MUGA) or echocardiography (ECHO)
Left ventricular ejection fraction (LVEF) within institutional range of normal as measured by echocardiogram (ECHO); multigated acquisition (MUGA) scans will be accepted in cases where an echocardiogram cannot be performed or is inconclusive (LVEF of > 50% required if normal range LVEF is not provided by institution)
Baseline (< 1 month before treatment) cardiac left ventricular function with resting ejection fraction of less than 50% measured by multigated blood pool imaging of the heart (MUGA scan) or echocardiogram
Left ventricular ejection fraction (LVEF) >= 50% as determined by a multigated acquisition (MUGA) scan or echocardiogram
Left ventricular ejection fraction by multigated acquisition scan (MUGA) or echocardiogram >= 55% for patients with triple negative breast cancer; >= upper limit of institutional normal for patient with HR+ breast cancer within 7 days of treatment initiation
Left ventricular ejection fraction =< 50% as demonstrated by echocardiogram or multigated acquisition scan (MUGA)
Patients with left ventricular ejection fraction < 50% on echocardiogram or multigated acquisition scan will be excluded
Baseline multigated acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= 50%
Cardiac ejection fraction >= 40% (by either cardiac echocardiogram [echo] or multigated acquisition [MUGA] scan); documentation of recent (=< 6 months from screening) outside reports is acceptable
Adequate organ function defined by the screening laboratory inclusion listed below and Left Ventricular Ejection Fraction (LVEF) ? 45% confirmed by ECHO or multigated acquisition (MUGA)
Left ventricular ejection fraction (LVEF) >= 40% (multigated acquisition scan [MUGA] or echocardiogram)
All patients must have an echo or multigated acquisition (MUGA) scan showing ejection fraction (EF) > 50% and normal troponin and creatine kinase MB (CK MB) performed within 90 days of starting treatment
Cardiac ejection fraction >= 50%, as measured by echocardiography (ECHO) or multigated acquisition scan (MUGA)
Left ventricular ejection fraction (LVEF) >= 50% as determined by a multigated acquisition (MUGA) scan or echocardiogram
Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multigated acquisition scan (MUGA)
Symptomatic left ventricular dysfunction or baseline left ventricular ejection fraction (LVEF) by multigated acquisition scan (MUGA) or echocardiogram (ECHO) =< 50% lower limit of institutional normal (LLN)
Left ventricular ejection fraction (LVEF) > 40% (by echocardiogram [ECHO] or multigated acquisition scan [MUGA])
Left ventricular ejection fraction (LVEF) >= 50% by either echocardiogram (ECHO) or multigated acquisition scan (MUGA)
Left ventricular ejection fraction (LVEF) >= 40% within 30 days before cycle 1 day 1; 2-dimensional (2-D) transthoracic echocardiogram (ECHO) is the preferred method of evaluation; multigated acquisition (MUGA) is acceptable if ECHO is not available
Patients must have a pre-study echocardiogram or multigated acquisition (MUGA) scan with an actual left ventricular ejection fraction of greater than or equal to the institution lower limit of normal within one month prior to start of study.
Left ventricular ejection fraction (LVEF) ?institutional lower limit of normal as measured by multigated acquisition scan (MUGA) or 2-dimensional (2-D) echocardiography (ECHO) within 28 days prior to start of therapy and no clinically significant abnormalities on a 12-lead electrocardiogram (ECG)
All patients must have an left ventricular ejection fraction (LVEF) measurement of at least 50% by echocardiogram (ECHO) or multigated acquisition scan (MUGA) (if clinically indicated) within 14 days prior to registration; the method used for LVEF assessment in an individual subject must be the same throughout the trial
Left ventricular ejection fraction > 50% on echocardiography or multigated acquisition (ECHO/MUGA) scan
Left ventricular ejection fraction (LVEF) >= 50% as determined by a multigated acquisition (MUGA) scan or echocardiogram (ECHO)
Uncontrolled or severe cardiovascular disease or left ventricular ejection fraction < 50% as determined by echocardiogram or multigated acquisition scan (MUGA)
A resting ejection fraction of 50% or greater which increases with exercise as demonstrated by resting/exercise multigated acquisition (MUGA) or ejection fraction of 50% or greater by echocardiogram
Left ventricular ejection fraction (LVEF) greater or equal to 50% at baseline as determined by either echocardiogram (ECHO) or multigated acquisition (MUGA)
Left ventricular ejection fraction (LVEF) >= 50% by multigated acquisition scan (MUGA) scan or echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) >= 45% by multigated acquisition (MUGA) scan or echocardiogram
Subject has left ventricular ejection fraction (LVEF) ? 50%, or below institution's lower limit of normal (whichever is lower) by echocardiogram (ECHO) or multigated acquisition (MUGA) scan.
Have current or a history of congestive heart failure New York Heart Association (NYHA) class 3 or 4, or any history of documented diastolic or systolic dysfunction (left ventricular ejection fraction [LVEF] < 40%, as measured by multigated acquisition [MUGA] scan or echocardiogram)
Has left ventricular ejection fraction (LVEF) < 45% by either echocardiogram (ECHO) or multigated acquisition scan (MUGA)
Left ventricular ejection fraction (LVEF) > lower limit of normal (LLN) based on cardiac echocardiography (ECHO) or multi-gated acquisition (MUGA)
Left ventricular ejection fraction >= 50% by transthoracic echocardiography or multi-gated acquisition scan (MUGA) within 28 days prior to the first dose of the study drug
Left ventricular ejection fraction (LVEF) greater than 50% on echocardiography or multiple gated acquisition (MUGA) scan
Left ventricular ejection fraction of > 50% on baseline echocardiography or multi-gated acquisition (MUGA) scan
Participants must have adequate cardiac function, e.g. left ventricular ejection fraction (LVEF) of > 50% as assessed by multi-gated acquisition (MUGA) or ultrasound/echocardiography (ECHO); corrected QT interval (QTc) < 470ms
Left ventricular ejection fraction (LVEF) >= 40% by echocardiography, multigated acquisition (MUGA), or cardiac magnetic resonance imaging (MRI); no uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities (within 28 days of study registration)
Left ventricular ejection fraction of 50% or more at baseline (by echocardiography or multiple-gated acquisition scanning)
Left ventricular ejection fraction (LVEF) >= 40% by echocardiography or multi-gated acquisition scan (MUGA) or cardiac magnetic resonance imaging (MRI), no uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
Impaired cardiac function (left ventricular ejection fraction [LVEF] < 40%) as assessed by echocardiography (ECHO) or radionuclide ventriculogram (MUGA) scan
Left ventricular ejection fraction (LVEF) >= 40% by echocardiography or multi-gated acquisition scan (MUGA), no uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
Left ventricular ejection fraction (LVEF) >= 45%, assessed within 3 months prior to registration, e.g. by multigated acquisition (MUGA) scan or echocardiography, or other appropriate diagnostic modality
Patient has no significant ischemic heart disease or myocardial infarction (MI) within 6 months before the first dose of TVB 2640 and currently has adequate cardiac function, as evidenced by a left ventricular ejection fraction (LVEF) of >= 50% as assessed by multi-gated acquisition (MUGA) or ultrasound/echocardiography (ECHO); and corrected QT interval (QTc) < 470 msec on screening electrocardiogram (EKG)
Left ventricular ejection fraction (LVEF) of lesser than [<] 50 percent (%) as determined by multiple uptake gated acquisition (MUGA) or echocardiography during screening
Left ventricular ejection fraction >= 45%, assessed within 3 months prior to registration, e.g. by multigated acquisition scan (MUGA) scan or echocardiography, or other appropriate diagnostic modality and no clinical evidence of congestive heart failure; if the patient had anthracycline-based therapy since the most recent cardiac assessment, cardiac evaluation should be repeated if there is clinical or radiographic suspicion of cardiac dysfunction, or if the previous cardiac assessment was abnormal
Left ventricular ejection fraction >= 45%, assessed within 3 months prior to study day 0, e.g. by multi gated acquisition scan (MUGA) scan or echocardiography, or other appropriate diagnostic modality and no clinical evidence of congestive heart failure
Baseline (pre-HCT) multi-gated acquisition (MUGA) or echocardiography (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= the lower limit of normal (LLN) of the institutional normal
Left ventricular ejection fraction (LVEF) < 50 as determined by multi gated acquisition scan (MUGA) scan or echocardiography (ECHO)
Cardiac function >= international lower limit of normal (ILLN), e.g., left ventricular ejection fraction (LVEF) of > 50% as assessed by multi gated acquisition scan (MUGA) or echocardiography (ECHO), corrected QT interval (QTc) < 470 ms
Left ventricle ejection fraction (LVEF) >= 40% confirmed by echocardiography (ECHO)/ multi gated acquisition scan (MUGA)
Left ventricular ejection fraction (by transthoracic echocardiography [TTE], multigated acquisition scan [MUGA] or cardiac magnetic resonance imaging [MRI]) sufficient to safely administer mitoxantrone as determined by the treating physician
Adequate cardiac function as evidenced by left ventricular ejection fraction (LVEF) greater than or equal to 50%) at baseline as determined by echocardiography.
Left ventricular ejection fraction equal to or greater than normal within 1 month of enrollment; echocardiography (ECHO) scans must be used throughout the study
Left ventricular ejection fraction must be evaluated by nuclear medicine scan or echocardiography and measure >= 50%
No cardiac (left ventricular ejection fraction [LVEF] > 50% by multigated acquisition scan [MUGA] or three-dimensional echocardiography [TTE]; if LVEF > 40% but < 50% by MUGA or TTE MUST HAVE cardiology evaluation and clearance for ASCT)
Adequate cardiac function (left ventricular ejection fraction [LVEF] >= 40%) as assessed by echocardiography (ECHO) or multigated acquisition (MUGA) scan performed within 1 month of treatment
No active symptomatic ischemic heart disease, myocardial infarction or congestive heart failure within the past year; if multi gated acquisition (MUGA) is obtained, the left ventricular ejection fraction (LVEF) should exceed 40%
Left ventricular ejection fraction ? 45%, assessed within 12 months prior to study day 0, e.g. by multigated acquisition (MUGA) scan or echocardiography, or other appropriate diagnostic modality and no clinical evidence of congestive heart failure
Within 14 days of study registration (30 days for pulmonary and cardiac): left ventricular ejection fraction (LVEF) >= 40% by echocardiography or multigated acquisition (MUGA), no uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
Presence of left ventricular thrombus as documented by echocardiography or left ventriculogram
Left ventricular systolic dysfunction, defined as ejection fraction below institutional normal by echocardiography or multi-gated acquisition scan (MUGA); or current or past clinical diagnosis of congestive heart failure; history of ejection fraction decreased to below institutional normal or decrease of greater than 15% attributable to past trastuzumab or pertuzumab therapy
CLINICAL/LABORATORY CRITERIA: Patients must have a left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (ILLN) by echocardiography (ECHO) or multi-gated acquisition scan (MUGA) within 42 days prior to registration
Left ventricular ejection fraction (LVEF) greater than 50% on echocardiography or multiple gated acquisition (MUGA) scan.
Cardiac ejection fraction >= 50% by echocardiography or multi gated acquisition (MUGA) (when left ventricular ejection fraction [LVEF] expressed as a range, at least the upper limit should include 50%)
Left ventricular ejection fraction >= 45%, assessed within 3 months prior to study day 0, e.g. by multi gated acquisition scan (MUGA) scan or echocardiography, or other appropriate diagnostic modality and no clinical evidence of congestive heart failure; if the patient had anthracycline-based therapy since the most recent cardiac assessment, cardiac evaluation should be repeated if there is clinical or radiographic suspicion of cardiac dysfunction, or if the previous cardiac assessment was abnormal
Intraventricular septal (IVS) thickness =< 25 mm (as determined by 2-dimensional [2D] echocardiography or cardiac magnetic resonance imaging [MRI]) (ejection fraction may also be assessed by a multi-gated acquisition [MUGA])
Cardiac ejection fraction >= 45% by echocardiography (transthoracic echocardiography) or multi gated acquisition scan (MUGA) scan
Left ventricular ejection fraction within institutional normal limits, as determined by echocardiography or multiple uptake gated acquisition (MUGA) scan
Left ventricular ejection fraction (LVEF) must be >= the lower limit of normal (LLN) per institutional standards by either echocardiography or radionuclide-based multiple gated acquisition (MUGA)
Left ventricular ejection fraction (LVEF) >= 50% (as assessed by echocardiography [ECHO] or multigated acquisition [MUGA]) documented within 4 weeks prior to first dose of study treatment
Adequate cardiac function (left ventricular ejection fraction [LVEF] ?50% measured by echocardiography or multi-gated acquisition [MUGA] scan)
Normal (greater than 50%) left ventricular ejection fraction (LVEF) by multi gated acquisition (MUGA) scan or echocardiography
Baseline left ventricular ejection fraction (LVEF) less than (<) 50%, documented by echocardiography, multiple-gated radionuclide angiography (MUGA) scan, or cardiac magnetic resonance imaging (MRI)
Left ventricular ejection fraction (LVEF) >= 45 % (by multigated acquisition scan [MUGA] or echocardiography)
Baseline of Left Ventricular Ejection Fraction (LVEF) ?50% measured by echocardiography (ECHO) or multi-gated acquisition scan (MUGA)
Left ventricular ejection fraction (LVEF) >= 40%, assessed within 28 days prior to registration, e.g. by multi gated acquisition (MUGA) scan or echocardiography, or other appropriate diagnostic modality
Left ventricular ejection fraction >= 40%, assessed within 3 months prior to study day 1, e.g. by multi gated acquisition (MUGA) scan or echocardiography, or other appropriate diagnostic modality and no clinical evidence of congestive heart failure; if the patient had anthracycline-based therapy since the most recent cardiac assessment, cardiac evaluation should be repeated if there is clinical or radiographical suspicion of cardiac dysfunction, or if the previous cardiac assessment was abnormal
Left ventricular ejection fraction (LVEF) less than 50 percent as assessed by echocardiography (or multi-gated acquisition) performed at screening
Normal (greater than 50%) left ventricular ejection fraction (LVEF) by multiple gated acquisition (MUGA) scan or echocardiography
Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) as assessed by echocardiography or multigated acquisition (MUGA) scan
Has a pre-treatment transthoracic echocardiography (TTE) showing a calculated left ventricular ejection fraction of less than 50%
Left ventricular ejection fraction (LVEF) >50% on echocardiography or multiple-gate acquisition (MUGA) scan.
Left ventricular ejection fraction (LVEF) by echocardiography (ECHO) or multiplegated acquisition (MUGA) within normal range (according to institutional standards).
Left ventricular ejection fraction (LVEF) < 40% as measured by echocardiography or MUGA scan performed at Screening
